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Background: Nephrotoxicity due to drugs especially beta lactams and cephalosporins has been well recognised.
Cefepime is a fourth-generation cephalosporin that is widely prescribed with few severe adverse reactions reported.
Although cefepime induced neurotoxicity has frequently been reported, there is yet no reported case of acute
interstitial nephritis caused by this drug. We report a biopsy proven case of acute kidney injury due to acute
interstitial nephritis associated with use of cefepime for treatment of mastoiditis and temporal bone osteomyelitis.
Case presentation: A 62-year-old Caucasian female presented with symptoms of right sided mastoiditis. A brain
Magnetic Resonance Imaging scan revealed presence of right sided mastoiditis with concurrent temporal bone
osteomyelitis. Microbiological specimen isolated an Escherichia coli. Therapy was commenced with intravenous
cefepime. After 4 weeks of therapy with intravenous cefepime she developed acute kidney injury. No other
medications were taken by the patient. Urine analysis revealed non-nephrotic range proteinuria. There was no
red cell casts or white cell casts. Renal biopsy confirmed acute interstitial nephritis as cause of acute kidney
injury. Cefepime therapy was ceased and treatment with ciprofloxacin was given to complete the treatment
course. Renal function improved only partially with conservative management without any corticosteroid use.
To our knowledge this is the first report of cefepime induced interstitial nephritis.
Conclusions: Although cefepime has been considered to be a safe antibiotic from nephrotoxicity point, like
other cephalosporins this adverse effect can occur rarely. Physicians need to be mindful of nephrotoxicity
associated with its use and careful monitoring of renal parameters should be performed in patients on
prolonged therapy with cefepime.
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Acute kidney injury (AKI) from acute tubular necrosis
and acute interstitial nephritis (AIN) are commonly seen
in clinical practice [1]. Approximately 20% of AKI cases
are caused by drug or toxins with potential increase in
morbidity and permanent renal dysfunction [2]. Nephro-
toxicity due to drugs can occur by various mechanisms
including changes in glomerular hemodynamics, tubular
toxicity, crystal nephropathy, obstruction, thrombotic
microangiopathy and acute interstitial nephritis [3].
The majority of cases of AIN (75%) are caused by drugs
with antibiotics accounting for approximately 25% of
these [4].* Correspondence: kmac0605@gmail.com
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unless otherwise stated.Cefepime is a parenteral fourth-generation cephalo-
sporin with an extended spectrum of antimicrobial activity
that is routinely prescribed for variety of hospital acquired
infections. It is considered well tolerated and is associated
with few adverse reactions. Cefepime-related neurological
toxicity is well described in patients with renal impairment
[5]. However with the exception of a rat model with
nephrotoxicity, till date no human report of nephrotox-
icity exists [6]. PubMed search conducted with keywords-
“cefepime”, “nephrotoxicity”, “acute interstitial nephritis”,
“acute kidney injury” did not reveal any case reports in lit-
erature. We believe this is the first report of such adverse
event arising from its use.
Case presentation
A 62 year old Caucasian female patient (height - 1.60 m,
weight 72 kg, BMI 28.1) was admitted to hospital withis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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and eGFR was 63 ml/min/1.73 m2 by MDRD equation)
whilst on treatment for mastoiditis. Her background
medical history included hypertension, and type 2 dia-
betes for which she was on regular sitagliptin-metformin
50/1000 mg half tablet twice a day, metoprolol 25 mg
twice daily, lisinopril 10 mg daily and simvastatin 40 mg
daily. She had a long medical history of recurrent otitis
media for which she required grommet insertion. She
was managed as outpatient with topical and oral ciprofloxa-
cin by her otolaryngologist. Trial of oral trimethoprim-
sulphamethaxazole (Bactrim DS) was prescribed without
much clinical improvement. Eight weeks prior to this
admission, she had symptoms of earache, localised post
auricular swelling and fever. A CT scan showed mas-
toiditis and a contiguous subperiosteal abscess. A brain
Magnetic Resonance Imaging (MRI) scan and Techne-
tium 99 m labelled bone scan which revealed osteomye-
litis (OM) of the petrous temporal bone (Figure 1). She
underwent an emergency cortical mastoidectomy with
drainage of the abscess and insertion of a new right ear
grommet. Empirical therapy with ticarcillin-clavulanate
(12.4 grams/day) was commenced.
A surface swab from the ear isolated Escherichia coli
(which was sensitive to ticarcillin-clavulanate, piperacillin-
tazobactam, cefepime and gentamicin, but resistant to
ceftriaxone and ciprofloxacin). Susceptibilities were done
using Vitek2 (Biomerieux, Marcy l’Etolie, France) using
standard Gram negative card. Based on the antibiogram
the isolate most likely had underlying extended spectrumFigure 1 MRI scan - T2 weighted image showing soft tissue oedema i
99 m scan showing increased uptake in the same area (right).beta lactamase, although confirmatory testing was not
done as per current testing policy (non-sterile site isolate).
The operative specimens of pus and tissue taken at the
time of surgery remained sterile. Her antibiotic was chan-
ged to cefepime (6 grams/day).
She made good progress and was discharged with a
plan of continuing cefepime for 6 weeks as treatment of
OM on ambulatory care basis. After 2 weeks of therapy,
she developed malaise and dysgeusia. At 4 weeks, she
developed renal impairment (serum creatinine-140 μmol/L)
and the cefepime dose was reduced to 4 grams/day. Her
blood pressure at time was 130/82 mmHg. There was no
fever, rash or peripheral oedema. Urine analysis done by
automated iQ200 (Iris Diagnostics, Chatsworth, CA) ma-
chine and manual phase contrast microscopy showed
WBC of <10 × 106 /L, no RBC and no presence of either
WBC/RBC casts. 24 hour urine collection (of 2.47 L) had
proteinuria of 0.77 g/day (normal range-0.08-0.15 g/day).
C reactive protein was 3 mg/L (normal < 5 mg/L). At week
5 into therapy, she was noted to have worsening AKI
(serum creatinine 225 μmol/L) and was admitted for fur-
ther investigation (Figure 2). She suffered the ‘injury stage’
of AKI according to Risk Injury Failure Loss of kidney
function and End stage renal failure (RIFLE) criteria and
stage 3 of Acute Kidney Injury Network (AKIN) classifica-
tion at admission [7]. At this stage she was also noted to
have serum potassium of 6.1 mmol/L (range 3.5-5 mmol/L)
,serum sodium of 148 mmol/L (range 135-145 mmol/L),
serum chloride was 90 mmol/L (range 97-107 mmol/L)
and blood urea of 15 mmol/L (range 2.5-7.5 mmol/L).n the region of the right mastoid (left-see arrow) and technetium
Figure 2 Temporal trend in the creatinine and eGFR of our patient (from 1st admission till most recent follow up). Note- the two lines
‘generalized high’ and ‘generalized low’ depict the values of serum creatinine. Blue arrow-Cefepime start date -28/9, red arrow Cefepime stop
date -5/11.
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anti-inflammatory drugs (NSAIDs), chinese herbal supple-
ments or any other form of naturotherapy that were taken
by her.
During her inpatient stay all medications except
metoprolol were ceased. Though she was clinically
euvolaemic and suffered from non-oliguric renal failure,
36 hours trial of intravenous hydration with normal sa-
line (0.9% w/v) at 80 ml/hour was administered with
minimal effect on serum creatinine, blood urea and
serum electrolytes. Marginal increase of urine output
was noted which was commensurate with the intraven-
ous fluid administered. Laboratory investigations of
aetiology of AKI were negative or not detected. This
included: Double stranded DNAs, ANCA, extractable
nuclear antigens, rheumatoid factor, serum and urine
protein electrophoresis, complement levels, immuno-
globulin subclasses, streptococcal serology and hepatitis
B and C serology. An ANA titre of 1:1280 (homogenous
pattern) was noted and was thought to be related as a
reaction due to cefepime therapy. Renal ultrasound re-
vealed normal renal size, parenchyma and no obstruct-
ive uropathy. A renal biopsy showed moderate tubular
atrophy with many intra-tubular casts in the medullary
area. A few tubules were distended with cellular debris
and acute inflammatory exudate (acute tubulitis). Mod-
erate interstitial fibrosis was present with patchy areas
of inflammatory infiltrates comprising predominantly
lymphocytes, plasma cells and neutrophils. Eosinophils
were not detected in the renal biopsy. Periodic acid
Schiff stain and Gomori -silver stain were negative onthe biopsy. Immunofluorescence staining was negative
for IgA, IgG, IgM, kappa and lambda light chains, C1q,
C3, amyloid and fibrinogen. Electron microscopy did
not reveal any glomerular abnormality. (Figure 3)
It was concluded that this patient had drug-induced
AIN, most likely related to cefepime. Cessation of the
antibiotic led to a rapid improvement in her renal func-
tion over a week and therefore it was decided to treat
her conservatively. The serum creatinine dropped from
295 μmol/L to 170 μmol/L within a week and then con-
tinued to trend downwards reaching up to 150 μmol/L
on her 2 weekly follow-up post discharge. Her symptoms
of malaise and dysgeusia had also abated at this visit. All
the electrolytes (sodium, potassium and chloride) includ-
ing blood urea were within normal ranges at this stage.
Corticosteroid was not administered due to partially
treated infection, diabetes and rapid improvement in
renal function after cessation of antibiotics.
For completion of therapy (another 2 weeks) oral cip-
rofloxacin 500 mg twice daily was commenced, mindful
of the fact that the isolate was resistant to ciprofloxacin
with a minimal inhibitory concentration of 4 mg/L. Fol-
lowing discharge from hospital, she remained asymp-
tomatic and continued to improve from her infection
perspective. Sitagliptin-metformin, lisinopril and simva-
statin were slowly reintroduced over the next 3 months
after discharge while her renal function continued to
improve.
Table 1 shows the temporal trend in the biochemical
parameters including serum creatinine and eGFR. Although
serum creatinine has plateaued, mild renal impairment still
Figure 3 Renal biopsy showed interstitial fibrosis with patchy areas of inflammatory cells infiltration. Haematoxylin & Eosin stain x2.5, x40
hpf (red arrow-showing lymphocyte infiltration and interstitial fibrosis, yellow arrow-lymphocytes clusters).
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130 μmol/L and eGFR of 56 ml/min/1.73 m2).
This adverse drug reaction has been recorded perman-
ently in her electronic medical records and also has been
reported to Australian Therapeutic goods administration
(TGA).
Conclusions
We referred to the Naranjo criteria to report an adverse
drug event [8]. A score of 6 was derived using this criter-
ion rating this adverse reaction as “probable”. The limita-
tion of these criteria to determine an adverse effect of an
antibiotic is the difficulty of administering a placebo
(when serious infection is present) and effects of dose re-
duction (serious consequences in sepsis). Nephrotoxicity
was attributed to cefepime on basis on Naranjo criteria,
clinical onset of AKI, absence of any other nephrotoxic
drugs being administered and histopathological findings
of the renal biopsy.
Cefepime nephrotoxicity has been described in dose-
dependent manner in a rat model with increasing con-
centration of this antibiotic causing direct cytotoxic
damage to the renal tubules, manifesting as proteinuria,
glycosuria, and increase excretion of urinary sodium [6].
These could be attributed to the supratheurapeutic doses
administered in the animal study. Except for proteinuria
observed as altered urine microalbumin/creatinine ratio,Table 1 Changes in the biochemical parameters over course o
Parameter On admission
first hospital
Serum Creatinine (μmol/L) 89
eGFR (mL/min/1.73 m2) 60
CRP (mg/L) 3.0
Blood Eosinophil count (10^9/L) 0.1
Spot urine protein (g/L) ND
Spot urine microalbumin/creatinine ratio (mg/mmol Cr) ND
Spot urine protein/creatinine ratio (mg/mmol Cr) NDother biochemical abnormalities were not observed in
our patient. Cefepime was administered at maximally
recommended dosage (of 6 grams/day) as for a ‘serious
infection’ category which is also consistent with the
product information sheet. Data for use of this anti-
microbial in osteomyelitis is limited. Dosage regimens
for 2 grams every 12 hourly have been used for osteo-
myelitis due to Staphylococcus aureus and 2 grams every
8 hours for Gram negative infections [9,10]. The devel-
opment of AIN in our case could also be dose related as
seen in the rat model as maximal doses of the antimicro-
bial were used to treat the patient. Although cefepime
plasma levels of more than 22 mg/L have been found to
be predictive of neurotoxicity, it’s correlation with thera-
peutic monitoring is far from clear as target trough con-
centrations have not been established and the stability of
the drug itself in plasma is uncertain [11,12]. Optimal
and validated methods for therapeutic drug monitoring
of cefepime are needed before their routine use can be
performed in clinical context.
Other animal model studies have attributed toxicity of
cephalosporins to cortical AUC (area under the curve),
direct effect of the lactam ring and disruption of the
mitochondrial respiratory enzymes in the cortical tubular
cells [13,14]. Different classes within cephalosporins have
a different threshold of producing nephrotoxicity depend-
ing on their ionic charge and direct effect on the tubulesf time ND = Not done
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bility of toxic nephropathy as a cephalosporin class effect;
however this has not been described yet [16].
Most reports of antibiotic-related AIN describe its oc-
currence within the first three weeks particularly in the
first ten days of commencing the drug. However, a well
described delayed allergic reaction causing AIN has been
reported with drugs such as proton pump inhibitors and
mesalazine [17]. We hypothesize that two factors could
have contributed to the delay in clinical presentation- 1)
cefepime by itself acting as a hapten thereby eliciting de-
layed hypersensitivity reaction in the renal interstitium
and 2) slow metabolism of cefepime which could have
led to cumulative accumulation of N-methylpyrrolidine
(NMP) (active metabolite) that is known to nephrotoxic
in mice [18-20].
It is speculated that the lack of reported nephrotoxicity
could be attributed to the protective mechanisms against
oxidative damage (T suppressor cells) that exist in renal
tubules [18]. However this could be mitigated in genetic-
ally predisposed individuals. Renal biopsies on cases of
drug-induced AIN reveal a paucity of immune deposits,
however presence of interstitial infiltrates containing lym-
phocytes suggest that cell mediated immunity (delayed
hypersensitivity) plays an important role [20,21]. Inter-
action of tubular cells with lymphocytes increases intersti-
tial inflammation. Both these phenomena were observed
in the renal biopsy of our patient.
Although flank pain, haematuria and peripheral oedema
have been described as common manifestation of AIN,
they are present in <25% of cases [21,22]. None of these
findings were observed in our patient who experienced
malaise, dysgeusia early into her antibiotic therapy and
subsequently went on to develop an AKI. Various prog-
nostic factors have been studied in literature including
severity of interstitial fibrosis, presence of granulomas
and the fall of creatinine after AIN [23]. However they
do not predict full recovery. Despite a rapid decline
(over 2 weeks) in her serum creatinine after cessation of
the antibiotic, our patient’s renal function did not recover
to her baseline. Chronic impairment could be explained
by interstitial fibrosis observed in her renal biopsy.
Therapeutic role of corticosteroids is debatable with
evidence for its use based on small, non-randomized
case series. While some retrospective and uncontrolled
studies have shown benefit of early administration of
corticosteroids in preventing interstitial fibrosis, consistent
benefits have not been observed in others [24,25]. We
did not administer any adjunctive steroids as already
mentioned.
In summary, this is the first human case report of ce-
fepime induced AIN arising in the context of prolonged
use of this antibiotic. Awareness of this adverse effect
from this frequently prescribed antibiotic is importantfor the clinicians. We suggest careful monitoring of renal
parameters in patients who are likely to receive a pro-
longed course of this antibiotic as signs and symptoms
of AIN maybe subtle in the beginning of such an event.
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